Niven Ralph's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Jan 9, 2023
- Accession no.
- 0001415889-23-000708
- Filed
- Jan 9, 2023
- Trade date
- Jan 5, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 5 derivative transactions. Open-market sales total $59.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niven RalphCIK 0001168060 | Officer (CHIEF SCIENTIFIC OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2023 | Common Stock | MOption exerciseAcquired | +650 | $1.74 | +$1,131 | 2,259 | Direct | |
| Jan 5, 2023 | Common Stock | MOption exerciseAcquired | +1,600 | $2.14 | +$3,424 | 3,859 | Direct | |
| Jan 5, 2023 | Common Stock | SSaleDisposed | −2,250 | $26.40F2 | −$59,400 | 1,609 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2023 | Common Stock | MOption exerciseDisposed | −450 | $0.00 | $0 | 21,408 | Direct | |
| Jan 5, 2023 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 13,288 | Direct | |
| Jan 5, 2023 | Common Stock | MOption exerciseDisposed | −200 | $0.00 | $0 | 15,094 | Direct | |
| Jan 5, 2023 | Common Stock | MOption exerciseDisposed | −650 | $0.00 | $0 | 46,008 | Direct | |
| Jan 5, 2023 | Common Stock | MOption exerciseDisposed | −750 | $0.00 | $0 | 55,232 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.21 to $26.74, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.